TrovaGene Licenses SF3B1 Mutations, Plans LDT | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – TrovaGene today announced it is licensing mutations of the SF3B1 splicing factor, which have been associated with disease progression and chemotherapy response in patients with chronic lymphocytic leukemia.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Ivanka Trump and Secretary of Education Betsy DeVos call on girls to pursue STEM careers, the Associated Press reports.

Some science companies will be taking part in next month's March for Science, Fortune reports.

In Genome Research this week: longitudinal study of Burkholderia cenocepacia isolates from cystic fibrosis patients, long-read assembly approach, and more.

Shale oil companies are turning to DNA sequencing to find spots to drill, Reuters reports.